Literature DB >> 18794077

Translational Research Working Group developmental pathway for immune response modifiers.

Martin A Cheever1, Jeffrey Schlom, Louis M Weiner, H Kim Lyerly, Mary L Disis, Addison Greenwood, Oren Grad, William G Nelson.   

Abstract

The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. The Translational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794077      PMCID: PMC6383515          DOI: 10.1158/1078-0432.CCR-08-1266

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

Review 1.  Multiple vaccinations: friend or foe.

Authors:  Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 2.  Combining immunotherapy and radiotherapy in lung cancer.

Authors:  Neeraj Bhalla; Rachel Brooker; Michael Brada
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

Review 4.  Combining radiotherapy and cancer immunotherapy: a paradigm shift.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  J Natl Cancer Inst       Date:  2013-01-04       Impact factor: 13.506

Review 5.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 6.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

Review 7.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012

Review 8.  Influence of tumour micro-environment heterogeneity on therapeutic response.

Authors:  Melissa R Junttila; Frederic J de Sauvage
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

9.  In silico tumor control induced via alternating immunostimulating and immunosuppressive phases.

Authors:  A I Reppas; J C L Alfonso; H Hatzikirou
Journal:  Virulence       Date:  2015-08-25       Impact factor: 5.882

10.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.